skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Conivaptan: a step forward in the treatment of hyponatremia?

Review

(2549) Views  (488) Full article downloads

Authors: Su Su Hline, Phuong-Truc T Pham, Phuong-Thu T Pham, May H Aung, Phuong-Mai T Pham, Phuong-Chi T Pham

Published Date April 2008 Volume 2008:4(2) Pages 315 - 326
DOI: http://dx.doi.org/10.2147/TCRM.S340

Su Su Hline1, Phuong-Truc T Pham2, Phuong-Thu T Pham3, May H Aung1, Phuong-Mai T Pham4, Phuong-Chi T Pham1

1Olive View-UCLA Medical Center, Department of Medicine, Nephrology Division, Sylmar, CA, USA; 2Pennsylvania State Worthington Scranton, Dunmore, PA, USA; 3David Geffen School of Medicine at UCLA Medical Center, Los Angeles, CA, USA; 4Mather VA Medical Center, Mather, CA, USA

Abstract: Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes V1A, V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as “aquaretics,” has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.

Keywords: conivaptan, hyponatremia, euvolemia, hypervolemia, AVP, AVP receptor antagonist








Readers of this article also read:

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
New approaches to managing asthma: a US perspective
A review of nasal polyposis
Fluticasone furoate nasal spray in the treatment of allergic rhinitis
Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
Managing elevated intraocular pressure in a patient with optic nerve hypoplasia
Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma